FIELD: medicine, skin transplantation. SUBSTANCE: composition equivalent of living skin comprises epidermal layer of cultured keratinocytes, layer of porousless collagen and dermal layer of cultured fibroblasts in spongy matrix cross-linked by porous collagen. Preferable porousless collagen is bovine collagen of type 1, type 3 or their mixture treated with pepsin. Invention describes a method of skin equivalent preparing and test-set for the skin equivalent testing in vitro. Indicated skin equivalent can be used for skin transplantation and for assay of effects of different substances on skin in vitro. EFFECT: broadened functional capabilities. 8 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING PATIENT'S ORAL DISEASES (VERSIONS) | 2007 |
|
RU2498808C9 |
| SKIN EQUIVALENT AND METHOD FOR ITS PRODUCTION | 2006 |
|
RU2342164C2 |
| OCCLUDER FOR TRANSCUTANEOUS TRANSLUMINAL PROCEDURE (VERSIONS), METHOD OF TRANSCUTANEOUS TRANSLUMINAL CLOSING OF HOLE IN HEART, METHOD OF ACTIVISATION OF MAMMALIAN TISSUE VASCULARISATION IN VIVO AND METHOD OF ACTIVISATION OF ANASTOMOSIS PLACE HEALING | 2007 |
|
RU2470611C2 |
| ENGINEERED LEATHER EQUIVALENT, METHOD FOR PRODUCTION THEREOF AND PRODUCTS OBTAINED THEREFROM | 2017 |
|
RU2820590C2 |
| STERILE AUTOLOGOUS, ALLOGENIC OR XENOGENIC IMPLANTS AND METHOD FOR MAKING IT | 2008 |
|
RU2478403C2 |
| METHOD FOR TREATMENT OF PATIENTS WITH CONGENITAL EPIDERMOLYSIS BULLOSA BY COMBINED USE OF HUMAN ALLOGENEIC FIBROBLASTS AND LIVING SKIN EQUIVALENT | 2020 |
|
RU2779997C2 |
| BIOLOGICALLY ACTIVE WOUND COVERING | 2009 |
|
RU2430743C2 |
| BIOACTIVE COMPLEX FOR ORGANOGENESIS | 2003 |
|
RU2254146C2 |
| LIVE SKIN SUBSTITUENT, METHOD OF ITS PREPARING AND METHOD OF LIVE SKIN LESION TREATMENT | 1993 |
|
RU2104039C1 |
| COMPOSITIONS SUITABLE TO TREAT DERMAL SIGNS OF AGING | 2005 |
|
RU2409290C2 |
